RESUMO
HLA-DPB1*05:01:21 differs from HLA-DPB1*05:01:01:01 by one nucleotide in exon 3.
Assuntos
Cadeias beta de HLA-DP , Nucleotídeos , Humanos , Alelos , Sequência de Bases , ChinaRESUMO
HLA-DPA1*02:117 differs from HLA-DPA1*02:02:02:01 by one nucleotide in exon 2.
Assuntos
Cadeias alfa de HLA-DP , Nucleotídeos , Humanos , Alelos , Cadeias alfa de HLA-DP/genética , China , Análise de Sequência de DNARESUMO
HLA-C*17:69 differs from HLA-C*17:01:01:02 by one nucleotide in exon 4.
Assuntos
Antígenos HLA-C , Nucleotídeos , Humanos , Antígenos HLA-C/genética , Alelos , Sequência de Bases , China , Análise de Sequência de DNARESUMO
HLA-C*03:651 differs from HLA-C*03:03:01:01 by one nucleotide in exon 4.
Assuntos
Antígenos HLA-C , Nucleotídeos , Humanos , Antígenos HLA-C/genética , Alelos , Sequência de Bases , China , Análise de Sequência de DNARESUMO
HLA-B*40:555 differs from HLA-B*40:01:02:01 by one nucleotide in exon 3.
Assuntos
Antígenos HLA-B , Nucleotídeos , Humanos , Alelos , Análise de Sequência de DNA , Antígenos HLA-B/genética , ChinaRESUMO
HLA-B*15:659 differs from HLA-B*15:02:01:01 by one nucleotide in exon 2.
Assuntos
Alelos , Povo Asiático , Sequência de Bases , Éxons , Teste de Histocompatibilidade , Análise de Sequência de DNA , Humanos , Povo Asiático/genética , Análise de Sequência de DNA/métodos , Antígeno HLA-B15/genética , Antígeno HLA-B15/imunologia , Alinhamento de Sequência , Códon , Doadores de Tecidos , População do Leste AsiáticoRESUMO
HLA-B*40:550 differs from HLA-B*40:01:02:01 by one nucleotide in exon 1.
Assuntos
Éxons , Antígeno HLA-B40 , Teste de Histocompatibilidade , Humanos , Alelos , Sequência de Bases , Códon , População do Leste Asiático , Antígeno HLA-B40/genética , Alinhamento de Sequência , Análise de Sequência de DNA/métodosRESUMO
HLA-DPB1*1553:01 differs from HLA-DPB1*09:01:01:01 by one nucleotide in exon 3.
Assuntos
Éxons , Cadeias beta de HLA-DP , Teste de Histocompatibilidade , Humanos , Alelos , Sequência de Bases , Códon , População do Leste Asiático , Cadeias beta de HLA-DP/genética , Alinhamento de Sequência , Análise de Sequência de DNA/métodos , Doadores de TecidosRESUMO
Purpose: The objective of this study was to provide theoretically feasible strategies by understanding the relationship between the immune microenvironment and the diagnosis and prognosis of AML patients. To this end, we built a ceRNA network with lncRNAs as the core and analyzed the related lncRNAs in the immune microenvironment by bioinformatics analysis. Methods: AML transcriptome expression data and immune-related gene sets were obtained from TCGA and ImmPort. Utilizing Pearson correlation analysis, differentially expressed immune-related lncRNAs were identified. Then, the LASSO-Cox regression analysis was performed to generate a risk signature consisting immune-related lncRNAs. Accuracy of signature in predicting patient survival was evaluated using univariate and multivariate analysis. Next, GO and KEGG gene enrichment and ssGSEA were carried out for pathway enrichment analysis of 183 differentially expressed genes, followed by drug sensitivity and immune infiltration analysis with pRRophetic and CIBERSORT, respectively. Cytoscape was used to construct the ceRNA network for these lncRNAs. Results: 816 common lncRNAs were selected to acquire the components related to prognosis. The final risk signature established by multivariate Cox and stepwise regression analysis contained 12 lncRNAs engaged in tumor apoptotic and metastatic processes: LINC02595, HCP5, AC020934.2, AC008770.3, LINC01770, AC092718.4, AL589863.1, AC131097.4, AC012368.1, C1RL-AS1, STARD4-AS1, and AC243960.1. Based on this predictive model, high-risk patients exhibited lower overall survival rates than low-risk patients. Signature lncRNAs showed significant correlation with tumor-infiltrating immune cells. In addition, significant differences in PD-1/PD-L1 expression and bleomycin/paclitaxel sensitivity were observed between risk groups. Conclusion: LncRNAs related to immune microenvironment were prospective prognostic and therapeutic options for AML.